Arenicin-1 vs Efinopegdutide
Head-to-head comparison of Arenicin-1 (Arenicin-1) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Arenicin-1 | Efinopegdutide |
|---|---|---|
| Category | Marine-Derived | Weight Management |
| Full Name | Arenicin-1 | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 2079 Da | N/A |
| Half-Life | n/a | Approximately 1 week |
| Amino Acids | 21 | N/A |
| Typical Dose | n/a | Trial-dependent; weekly SC dosing |
| Route | preclinical | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 76 | 14 |
| Research Status | Pre-clinical | Clinical |
Arenicin-1 Benefits
- ✓antimicrobial
- ✓anti-biofilm
- ✓membrane-active
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Arenicin-1 Dosing
bacterial infection|biofilm disruption
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Arenicin-1 Side Effects
- ⚠Arenicola marina
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Arenicin-1
Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.